Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Lung Cancer

Retrieve available abstracts of 324 articles:
HTML format
Text format



Single Articles


    September 2017
  1. ROUSSEAU-GAZANIOL C, Fraboulet S, Couderc LJ, Kreis H, et al
    Lung cancer in renal transplant recipients: A case-control study.
    Lung Cancer. 2017;111:96-100.
    PubMed     Text format     Abstract available


  2. MIURA K, Hamanaka K, Koizumi T, Kitaguchi Y, et al
    Clinical significance of preoperative serum albumin level for prognosis in surgically resected patients with non-small cell lung cancer: Comparative study of normal lung, emphysema, and pulmonary fibrosis.
    Lung Cancer. 2017;111:88-95.
    PubMed     Text format     Abstract available


  3. LIM SM, Chang H, Cha YJ, Liang S, et al
    Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lung Cancer. 2017;111:79-83.
    PubMed     Text format     Abstract available


  4. MOON SM, Lee DG, Hwang NY, Ahn S, et al
    Ipsilateral pleural recurrence after diagnostic transthoracic needle biopsy in pathological stage I lung cancer patients who underwent curative resection.
    Lung Cancer. 2017;111:69-74.
    PubMed     Text format     Abstract available


  5. TOKACA N, Wotherspoon A, Nicholson AG, Fotiadis N, et al
    Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
    Lung Cancer. 2017;111:65-68.
    PubMed     Text format     Abstract available


  6. CAPELAN M, Roda D, Geuna E, Rihawi K, et al
    Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
    Lung Cancer. 2017;111:6-11.
    PubMed     Text format     Abstract available


  7. CALIFANO R, Greystoke A, Lal R, Thompson J, et al
    Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Lung Cancer. 2017;111:51-58.
    PubMed     Text format     Abstract available


  8. SHEN L, Niu X, Jian H, Xu Y, et al
    Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2017;111:43-50.
    PubMed     Text format     Abstract available


  9. MORIKAWA N, Inoue A, Sugawara S, Maemondo M, et al
    Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naive extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
    Lung Cancer. 2017;111:38-42.
    PubMed     Text format     Abstract available


  10. GOBBINI E, Galetta D, Tiseo M, Graziano P, et al
    Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.
    Lung Cancer. 2017;111:30-37.
    PubMed     Text format     Abstract available


  11. LABBE C, Cabanero M, Korpanty GJ, Tomasini P, et al
    Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Lung Cancer. 2017;111:23-29.
    PubMed     Text format     Abstract available


  12. HATA A, Katakami N, Nanjo S, Okuda C, et al
    Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2017;111:182-189.
    PubMed     Text format     Abstract available


  13. DIEM S, Schmid S, Krapf M, Flatz L, et al
    Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Lung Cancer. 2017;111:176-181.
    PubMed     Text format     Abstract available


  14. SCULIER C, Bentea G, Ruelle L, Grigoriu B, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions.
    Lung Cancer. 2017;111:164-175.
    PubMed     Text format     Abstract available


  15. RUELLE L, Bentea G, Sideris S, El Koulali M, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles.
    Lung Cancer. 2017;111:150-163.
    PubMed     Text format     Abstract available


  16. WOHLKOENIG C, Leithner K, Olschewski A, Olschewski H, et al
    TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1alpha.
    Lung Cancer. 2017;111:15-22.
    PubMed     Text format     Abstract available


  17. YOUSAF-KHAN AU, van der Aalst CM, Aerts JGJV, den Bakker MA, et al
    Uniform and blinded cause of death verification of the NELSON lung cancer screening participants.
    Lung Cancer. 2017;111:131-134.
    PubMed     Text format     Abstract available


  18. GAGLIASSO M, Migliaretti G, Ardissone F
    Assessing the prognostic impact of the International Association for the Study of Lung Cancer proposed definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer surgery.
    Lung Cancer. 2017;111:124-130.
    PubMed     Text format     Abstract available


  19. TAGHIZADEH N, Taylor KL, MacEachern P, Koetzler R, et al
    Tobacco use and motivation to stop smoking among long-term smokers who are ineligible for lung cancer screening.
    Lung Cancer. 2017;111:101-107.
    PubMed     Text format     Abstract available


  20. FUJIMOTO D, Morimoto T, Ito J, Sato Y, et al
    A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
    Lung Cancer. 2017;111:1-5.
    PubMed     Text format     Abstract available


    August 2017
  21. VON VERSCHUER U, Schnell R, Tessen HW, Eggert J, et al
    Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study.
    Lung Cancer. 2017 Aug 22. pii: S0169-5002(17)30419.
    PubMed     Text format     Abstract available


  22. CHENG YW, Chiou HL, Chen JT, Chou MC, et al
    Corrigendum to: 'Gender difference in human papillomarvirus infection for non-small cell lung cancer in Taiwan' [Lung Cancer 46 (November(2)) (2004) 165-170].
    Lung Cancer. 2017 Aug 18. pii: S0169-5002(17)30486.
    PubMed     Text format    


  23. LIAO BC, Lin CC, Lee JH, Yang JC, et al
    Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
    Lung Cancer. 2017;110:7-13.
    PubMed     Text format     Abstract available


  24. KIM EY, Kim A, Kim SK, Chang YS, et al
    MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
    Lung Cancer. 2017;110:63-67.
    PubMed     Text format     Abstract available


  25. KIM SH, Hyun JW, Kim HJ, Gwak HS, et al
    De novo cystic brain lesions mimicking neurocysticercosis in ALK-positive lung cancer.
    Lung Cancer. 2017;110:53-55.
    PubMed     Text format     Abstract available


  26. TAO MH, Dai Q, Chen S, Freudenheim JL, et al
    Calcium plus vitamin D supplementation and lung cancer incidence among postmenopausal women in the Women's Health Initiative.
    Lung Cancer. 2017;110:42-47.
    PubMed     Text format     Abstract available


  27. KOBAYASHI-WATANABE N, Sato A, Watanabe T, Abe T, et al
    Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.
    Lung Cancer. 2017;110:35-41.
    PubMed     Text format     Abstract available


  28. SANDS J, Li Q, Hornberger J
    Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
    Lung Cancer. 2017;110:19-25.
    PubMed     Text format     Abstract available


  29. DICKHOFF C, Dahele M, Smit EF, Paul MA, et al
    Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry.
    Lung Cancer. 2017;110:14-18.
    PubMed     Text format     Abstract available


    July 2017
  30. LIU E, Guha A, Bertino E, Franco V, et al
    Cardiogenic shock in a patient being treated with atezolizumab for metastatic non-small cell lung cancer.
    Lung Cancer. 2017 Jul 29. pii: S0169-5002(17)30416.
    PubMed     Text format    


  31. SCHONEWOLF CA, Verma V, Post CM, Berman AT, et al
    Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
    Lung Cancer. 2017 Jul 14. pii: S0169-5002(17)30384.
    PubMed     Text format     Abstract available


  32. TAMURA T, Takagi Y, Okubo H, Yamaguchi S, et al
    Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis.
    Lung Cancer. 2017 Jul 8. pii: S0169-5002(17)30386.
    PubMed     Text format    


  33. YOSHIDA T, Kuroda H, Oya Y, Shimizu J, et al
    Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
    Lung Cancer. 2017;109:89-91.
    PubMed     Text format     Abstract available


  34. WAKEAM E, Acuna SA, Leighl NB, Giuliani ME, et al
    Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival.
    Lung Cancer. 2017;109:78-88.
    PubMed     Text format     Abstract available


  35. LOPEZ-PASTORINI A, Riedel R, Koryllos A, Beckers F, et al
    The impact of preoperative elevated serum C-reactive protein on postoperative morbidity and mortality after anatomic resection for lung cancer.
    Lung Cancer. 2017;109:68-73.
    PubMed     Text format     Abstract available


  36. ERIGUCHI T, Takeda A, Sanuki N, Tsurugai Y, et al
    Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.
    Lung Cancer. 2017;109:62-67.
    PubMed     Text format     Abstract available


  37. FUJISHITA T, Okamoto T, Akamine T, Takamori S, et al
    Association of MTH1 expression with the tumor malignant potential and poor prognosis in patients with resected lung cancer.
    Lung Cancer. 2017;109:52-57.
    PubMed     Text format     Abstract available


  38. GAO SJ, Kim AW, Puchalski JT, Bramley K, et al
    Indications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT.
    Lung Cancer. 2017;109:36-41.
    PubMed     Text format     Abstract available


  39. ZIEMKE M, Patil T, Nolan K, Tippimanchai D, et al
    Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
    Lung Cancer. 2017;109:28-35.
    PubMed     Text format     Abstract available


  40. O'KANE GM, Bradbury PA, Feld R, Leighl NB, et al
    Uncommon EGFR mutations in advanced non-small cell lung cancer.
    Lung Cancer. 2017;109:137-144.
    PubMed     Text format     Abstract available


  41. WAKEAM E, Varghese TK Jr, Leighl NB, Giuliani M, et al
    Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer.
    Lung Cancer. 2017;109:117-123.
    PubMed     Text format     Abstract available


  42. SUDA K, Rozeboom L, Rivard CJ, Yu H, et al
    Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
    Lung Cancer. 2017;109:1-8.
    PubMed     Text format     Abstract available


    June 2017
  43. GOROSPE L, Rioja-Martin ME, Santos-Carreno AL, Pacios-Blanco RE, et al
    Supraclavicular schwannoma mimicking a lymphadenopathy in a lung cancer patient: PET/CT findings.
    Lung Cancer. 2017 Jun 8. pii: S0169-5002(17)30354.
    PubMed     Text format    


  44. ZHAO J, Guerrero A, Kelnar K, Peltier HJ, et al
    Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
    Lung Cancer. 2017;108:96-102.
    PubMed     Text format     Abstract available


  45. GREENBERG V, Lazarev I, Frank Y, Dudnik J, et al
    Semi-automatic volumetric measurement of response to chemotherapy in lung cancer patients: How wrong are we using RECIST?
    Lung Cancer. 2017;108:90-95.
    PubMed     Text format     Abstract available


  46. IMPERATORI A, Sahnane N, Rotolo N, Franzi F, et al
    LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
    Lung Cancer. 2017;108:83-89.
    PubMed     Text format     Abstract available


  47. HIDAKA N, Iwama E, Kubo N, Harada T, et al
    Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
    Lung Cancer. 2017;108:75-82.
    PubMed     Text format     Abstract available


  48. GION M, Remon J, Caramella C, Soria JC, et al
    Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.
    Lung Cancer. 2017;108:72-74.
    PubMed     Text format     Abstract available


  49. NIHO S, Ohe Y, Ohmatsu H, Umemura S, et al
    Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
    Lung Cancer. 2017;108:66-71.
    PubMed     Text format     Abstract available


  50. MCEVOY SH, Halpenny DF, Viteri-Jusue A, Hayes SA, et al
    Investigation of patterns of nodal metastases in BRAF mutant lung cancer.
    Lung Cancer. 2017;108:62-65.
    PubMed     Text format     Abstract available


  51. YU XQ, Luo Q, Kahn C, Grogan P, et al
    Contrasting temporal trends in lung cancer incidence by socioeconomic status among women in New South Wales, Australia, 1985-2009.
    Lung Cancer. 2017;108:55-61.
    PubMed     Text format     Abstract available


  52. CROMBAG LMMJ, Szlubowski A, Stigt JA, Schuurbiers O, et al
    EUS-B-FNA vs conventional EUS-FNA for left adrenal gland analysis in lung cancer patients.
    Lung Cancer. 2017;108:38-44.
    PubMed     Text format     Abstract available


  53. SEKINE I, Harada H, Yamamoto N, Wakabayashi M, et al
    Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
    Lung Cancer. 2017;108:232-237.
    PubMed     Text format     Abstract available


  54. KOSHY M, Malik R, Spiotto M, Mahmood U, et al
    Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
    Lung Cancer. 2017;108:222-227.
    PubMed     Text format     Abstract available


  55. RUIZ-BANOBRE J, Perez-Pampin E, Garcia-Gonzalez J, Gomez-Caamano A, et al
    Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
    Lung Cancer. 2017;108:217-221.
    PubMed     Text format     Abstract available


  56. WEHLER T, Thomas M, Schumann C, Bosch-Barrera J, et al
    A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
    Lung Cancer. 2017;108:212-216.
    PubMed     Text format     Abstract available


  57. DRIESSEN EJ, Aarts MJ, Bootsma GP, van Loon JG, et al
    Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): Disparities between younger and older patients.
    Lung Cancer. 2017;108:198-204.
    PubMed     Text format     Abstract available


  58. YANG SC, Lai WW, Lin CC, Su WC, et al
    Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
    Lung Cancer. 2017;108:183-191.
    PubMed     Text format     Abstract available


  59. HARRIS JP, Patel MI, Loo BW, Wakelee HA, et al
    A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.
    Lung Cancer. 2017;108:173-182.
    PubMed     Text format     Abstract available


  60. MORAN T, Palmero R, Provencio M, Insa A, et al
    A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
    Lung Cancer. 2017;108:154-160.
    PubMed     Text format     Abstract available


  61. MORABITO A, Daniele G, Costanzo R, Favaretto AG, et al
    A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
    Lung Cancer. 2017;108:15-21.
    PubMed     Text format     Abstract available


  62. PATEL MI, McKinley M, Cheng I, Haile R, et al
    Lung cancer incidence trends in California by race/ethnicity, histology, sex, and neighborhood socioeconomic status: An analysis spanning 28 years.
    Lung Cancer. 2017;108:140-149.
    PubMed     Text format     Abstract available


  63. KRON F, Kostenko A, Scheffler M, Muller D, et al
    Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center.
    Lung Cancer. 2017;108:134-139.
    PubMed     Text format     Abstract available


  64. KANAJI N, Sakai K, Ueda Y, Miyawaki H, et al
    Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease.
    Lung Cancer. 2017;108:126-133.
    PubMed     Text format     Abstract available


  65. PATEL SH, Rimner A, Foster A, Zhang Z, et al
    Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.
    Lung Cancer. 2017;108:109-114.
    PubMed     Text format     Abstract available


  66. MIKUBO M, Nakashima H, Naito M, Matsui Y, et al
    Prognostic impact of uncertain parietal pleural invasion at adhesion sites in non-small cell lung cancer patients.
    Lung Cancer. 2017;108:103-108.
    PubMed     Text format     Abstract available


    April 2017
  67. SIMMONS CP, Koinis F, Fallon MT, Fearon KC, et al
    Corrigendum to "Prognosis in advanced lung cancer - A prospective study examining key clinicopathological factors" [Lung Cancer 88 (2015) 304-309].
    Lung Cancer. 2017 Apr 27. pii: S0169-5002(17)30302.
    PubMed     Text format    


  68. TANAKA N, Toyooka S, Soh J, Kubo T, et al
    Erratum to "Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer" [Lung Cancer 76 (1) (2012) 32-38].
    Lung Cancer. 2017 Apr 27. pii: S0169-5002(16)30299.
    PubMed     Text format    


  69. EDWARDS T, Balata H, Foden P, Crosbie P, et al
    Research letter: Evaluating the future pathological N descriptors for lung cancer staging in a UK population.
    Lung Cancer. 2017 Apr 15. pii: S0169-5002(17)30295.
    PubMed     Text format    


  70. HOLBRECHTS S, Gorham J, Sideris S, Meert AP, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes.
    Lung Cancer. 2017;106:93-101.
    PubMed     Text format     Abstract available


  71. BENTEA G, Sculier C, Grigoriu B, Meert AP, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system.
    Lung Cancer. 2017;106:83-92.
    PubMed     Text format     Abstract available


  72. FUJIWARA A, Shintani Y, Funaki S, Kawamura T, et al
    Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer.
    Lung Cancer. 2017;106:8-16.
    PubMed     Text format     Abstract available


  73. KIM DW, Garon EB, Jatoi A, Keefe DM, et al
    Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
    Lung Cancer. 2017;106:76-82.
    PubMed     Text format     Abstract available


  74. REMON J, Pardo N, Martinez-Marti A, Cedres S, et al
    Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
    Lung Cancer. 2017;106:70-75.
    PubMed     Text format     Abstract available


  75. MADDISON P
    Effects of aspirin on small-cell lung cancer mortality and metastatic presentation.
    Lung Cancer. 2017;106:67-69.
    PubMed     Text format     Abstract available


  76. SIMMONS VN, Gray JE, Schabath MB, Wilson LE, et al
    High-risk community and primary care providers knowledge about and barriers to low-dose computed topography lung cancer screening.
    Lung Cancer. 2017;106:42-49.
    PubMed     Text format     Abstract available


  77. LIU M, Wampfler JA, Dai J, Gupta R, et al
    Chest wall resection for non-small cell lung cancer: A case-matched study of postoperative pulmonary function and quality of life.
    Lung Cancer. 2017;106:37-41.
    PubMed     Text format     Abstract available


  78. HALPENNY DF, McEvoy S, Li A, Hayan S, et al
    Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics.
    Lung Cancer. 2017;106:33-36.
    PubMed     Text format     Abstract available


  79. IRIKI T, Ohnishi K, Fujiwara Y, Horlad H, et al
    The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation.
    Lung Cancer. 2017;106:22-32.
    PubMed     Text format     Abstract available


  80. KASAHARA N, Kenmotsu H, Serizawa M, Umehara R, et al
    Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2017;106:138-144.
    PubMed     Text format     Abstract available


  81. JONES BS, Jerome MS, Miley D, Jackson BE, et al
    Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2017;106:125-130.
    PubMed     Text format     Abstract available


  82. OU SI, Lee TK, Young L, Fernandez-Rocha MY, et al
    Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
    Lung Cancer. 2017;106:110-114.
    PubMed     Text format     Abstract available


  83. DURIEUX V, Coureau M, Meert AP, Berghmans T, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature.
    Lung Cancer. 2017;106:102-109.
    PubMed     Text format     Abstract available


  84. BAGLEY SJ, Kothari S, Aggarwal C, Bauml JM, et al
    Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2017;106:1-7.
    PubMed     Text format     Abstract available


    March 2017
  85. LI H, Yang T, Ning Q, Shang D, et al
    MicroRNA-505 modulates cancer proliferation and migration in human non-small cell lung cancer through inverse regulation of FZD4.
    Lung Cancer. 2017 Mar 31. pii: S0169-5002(17)30270.
    PubMed     Text format     Abstract available


  86. CAPELLETTO E, Mariniello A, Novello S
    Targeted therapy in small cell lung cancer: A new era?
    Lung Cancer. 2017 Mar 12. pii: S0169-5002(17)30258.
    PubMed     Text format    


  87. SALGIA R, Stille JR, Weaver RW, McCleod M, et al
    A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
    Lung Cancer. 2017;105:7-13.
    PubMed     Text format     Abstract available


  88. VERONESI G, Colombo P, Novellis P, Crepaldi A, et al
    Pilot study on use of home telephoning to identify and recruit high-risk individuals for lung cancer screening.
    Lung Cancer. 2017;105:39-41.
    PubMed     Text format     Abstract available


  89. GACHECHILADZE M, Skarda J, Kolek V, Grygarkova I, et al
    Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients.
    Lung Cancer. 2017;105:31-38.
    PubMed     Text format     Abstract available


  90. KATAKAMI N, Hida T, Nokihara H, Imamura F, et al
    Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
    Lung Cancer. 2017;105:23-30.
    PubMed     Text format     Abstract available


  91. SOO RA, Kim HR, Asuncion BR, Fazreen Z, et al
    Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2017;105:17-22.
    PubMed     Text format     Abstract available


  92. YONESAKA K, Hirotani K, von Pawel J, Dediu M, et al
    Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.
    Lung Cancer. 2017;105:1-6.
    PubMed     Text format     Abstract available


    February 2017
  93. TAYLOR KL, Hagerman CJ, Luta G, Bellini PG, et al
    Preliminary evaluation of a telephone-based smoking cessation intervention in the lung cancer screening setting: A randomized clinical trial.
    Lung Cancer. 2017 Feb 14. pii: S0169-5002(17)30029.
    PubMed     Text format     Abstract available


  94. SU XD, Xie HJ, Liu QW, Mo YX, et al
    The prognostic impact of tumor volume on stage I non-small cell lung cancer.
    Lung Cancer. 2017;104:91-97.
    PubMed     Text format     Abstract available


  95. SESUMI Y, Suda K, Mizuuchi H, Kobayashi Y, et al
    Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.
    Lung Cancer. 2017;104:85-90.
    PubMed     Text format     Abstract available


  96. KAWAGUCHI K, Yokoi K, Niwa H, Ohde Y, et al
    A prospective, multi-institutional phase II study of induction chemoradiotherapy followed by surgery in patients with non-small cell lung cancer involving the chest wall (CJLSG0801).
    Lung Cancer. 2017;104:79-84.
    PubMed     Text format     Abstract available


  97. AWAN S, Crosby V, Potter V, Hennig I, et al
    Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study.
    Lung Cancer. 2017;104:75-78.
    PubMed     Text format     Abstract available


  98. CHANG GC, Tseng CH, Hsu KH, Yu CJ, et al
    Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Lung Cancer. 2017;104:58-64.
    PubMed     Text format     Abstract available


  99. LAM VK, Bentzen SM, Mohindra P, Nichols EM, et al
    Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC).
    Lung Cancer. 2017;104:52-57.
    PubMed     Text format     Abstract available


  100. PAZ-ARES LG, Zimmermann A, Ciuleanu T, Bunn PA, et al
    Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2017;104:45-51.
    PubMed     Text format     Abstract available


  101. LILLIE SE, Fu SS, Fabbrini AE, Rice KL, et al
    What factors do patients consider most important in making lung cancer screening decisions? Findings from a demonstration project conducted in the Veterans Health Administration.
    Lung Cancer. 2017;104:38-44.
    PubMed     Text format     Abstract available


  102. KOH YW, Lee SJ, Park SY
    Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters.
    Lung Cancer. 2017;104:31-37.
    PubMed     Text format     Abstract available


  103. MESSARITAKIS I, Politaki E, Plataki M, Karavassilis V, et al
    Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.
    Lung Cancer. 2017;104:16-23.
    PubMed     Text format     Abstract available


  104. AWAD MM, Chu QS, Gandhi L, Stephenson JJ, et al
    An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
    Lung Cancer. 2017;104:126-130.
    PubMed     Text format     Abstract available


  105. KATO T, Masuda N, Nakanishi Y, Takahashi M, et al
    Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
    Lung Cancer. 2017;104:111-118.
    PubMed     Text format     Abstract available


  106. SHIN B, Shin S, Chung MJ, Lee H, et al
    Different histological subtypes of peripheral lung cancer based on emphysema distribution in patients with both airflow limitation and CT-determined emphysema.
    Lung Cancer. 2017;104:106-110.
    PubMed     Text format     Abstract available


  107. OKUMA Y, Hosomi Y, Nakahara Y, Watanabe K, et al
    High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Lung Cancer. 2017;104:1-6.
    PubMed     Text format     Abstract available


    January 2017
  108. SLOTMAN B
    What is the optimal radiotherapy schedule for limited stage small cell lung cancer?
    Lung Cancer. 2017 Jan 4. pii: S0169-5002(17)30002.
    PubMed     Text format     Abstract available


  109. GOW CH, Hsieh MS, Wu SG, Shih JY, et al
    A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
    Lung Cancer. 2017;103:82-89.
    PubMed     Text format     Abstract available


  110. THOMAS DC, Arnold BN, Rosen JE, Salazar MC, et al
    Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery.
    Lung Cancer. 2017;103:75-81.
    PubMed     Text format     Abstract available


  111. KANISKI F, Enewold L, Thomas A, Malik S, et al
    Temporal patterns of care and outcomes of non-small cell lung cancer patients in the United States diagnosed in 1996, 2005, and 2010.
    Lung Cancer. 2017;103:66-74.
    PubMed     Text format     Abstract available


  112. SAMSON P, Keogan K, Crabtree T, Colditz G, et al
    Interpreting survival data from clinical trials of surgery versus stereotactic body radiation therapy in operable Stage I non-small cell lung cancer patients.
    Lung Cancer. 2017;103:6-10.
    PubMed     Text format     Abstract available


  113. MCGOWAN M, Hoven AS, Lund-Iversen M, Solberg S, et al
    PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.
    Lung Cancer. 2017;103:52-57.
    PubMed     Text format     Abstract available


  114. REUNGWETWATTANA T, Liang Y, Zhu V, Ou SI, et al
    The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Lung Cancer. 2017;103:27-37.
    PubMed     Text format     Abstract available


  115. STAHL JM, Corso CD, Verma V, Park HS, et al
    Trends in stereotactic body radiation therapy for stage I small cell lung cancer.
    Lung Cancer. 2017;103:11-16.
    PubMed     Text format     Abstract available


  116. VON LAFFERT M, Schirmacher P, Warth A, Weichert W, et al
    ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer So
    Lung Cancer. 2017;103:1-5.
    PubMed     Text format     Abstract available


    December 2016
  117. MALIK N, Palma D
    Oligometastatic non-small cell lung cancer: Where do we go next?
    Lung Cancer. 2016 Dec 26. pii: S0169-5002(16)30581.
    PubMed     Text format    


  118. VRANCKEN A, Lepers S, Peeters L, Oyen C, et al
    The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database.
    Lung Cancer. 2016;102:96-100.
    PubMed     Text format     Abstract available


  119. HALVORSEN TO, Herje M, Levin N, Bremnes RM, et al
    Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer.
    Lung Cancer. 2016;102:9-14.
    PubMed     Text format     Abstract available


  120. LEE SH, Sung JY, Yong D, Chun J, et al
    Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions.
    Lung Cancer. 2016;102:89-95.
    PubMed     Text format     Abstract available


  121. HANNA NH, Kaiser R, Sullivan RN, Aren OR, et al
    Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
    Lung Cancer. 2016;102:65-73.
    PubMed     Text format     Abstract available


  122. TOMIZAWA K, Nishino M, Sesumi Y, Kobayashi Y, et al
    Prognostic impact of pleural lavage cytology in patients with primary lung cancer.
    Lung Cancer. 2016;102:60-64.
    PubMed     Text format     Abstract available


  123. GUPTA A, Majumder K, Arora N, Mayo HG, et al
    Premorbid body mass index and mortality in patients with lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2016;102:49-59.
    PubMed     Text format     Abstract available


  124. TANIZAKI J, Hayashi H, Kimura M, Tanaka K, et al
    Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.
    Lung Cancer. 2016;102:44-48.
    PubMed     Text format     Abstract available


  125. LEVACQ D, D'Haene N, de Wind R, Remmelink M, et al
    Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
    Lung Cancer. 2016;102:38-41.
    PubMed     Text format     Abstract available


  126. CICENAS S, Geater SL, Petrov P, Hotko Y, et al
    Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).
    Lung Cancer. 2016;102:30-37.
    PubMed     Text format     Abstract available


  127. LE FOURNIS S, Gohier P, Urban T, Jeanfaivre T, et al
    Corneal graft rejection in a patient treated with nivolumab for primary lung cancer.
    Lung Cancer. 2016;102:28-29.
    PubMed     Text format     Abstract available


  128. FUKUDA S, Oguri T, Kunii E, Sone K, et al
    A folylpoly-gamma-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer.
    Lung Cancer. 2016;102:15-20.
    PubMed     Text format     Abstract available


  129. DAI SD, Wang Y, Jiang GY, Zhang PX, et al
    RETRACTED: Kaiso is expressed in lung cancer: Its expression and localization is affected by p120ctn.
    Lung Cancer. 2016;102:141.
    PubMed     Text format    


  130. CHAPMAN AM, Sun KY, Ruestow P, Cowan DM, et al
    Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.
    Lung Cancer. 2016;102:122-134.
    PubMed     Text format     Abstract available


  131. WONG ML, McMurry TL, Stukenborg GJ, Francescatti AB, et al
    Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: A nationally representative cohort study.
    Lung Cancer. 2016;102:108-117.
    PubMed     Text format     Abstract available


    November 2016
  132. ROLFO C, Giallombardo M, Reclusa P, Sirera R, et al
    Exosomes in lung cancer liquid biopsies: Two sides of the same coin?
    Lung Cancer. 2016 Nov 18. pii: S0169-5002(16)30530.
    PubMed     Text format    


  133. GOFFIN JR, Flanagan WM, Miller AB, Fitzgerald NR, et al
    Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.
    Lung Cancer. 2016;101:98-103.
    PubMed     Text format     Abstract available


  134. SUZUKI Y, Okamoto T, Fujishita T, Katsura M, et al
    Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer.
    Lung Cancer. 2016;101:92-97.
    PubMed     Text format     Abstract available


  135. OHGAMI M, Kaburagi T, Kurosawa A, Homma M, et al
    Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer.
    Lung Cancer. 2016;101:9-10.
    PubMed     Text format     Abstract available


  136. BERNHARDT D, Bozorgmehr F, Adeberg S, Opfermann N, et al
    Outcome in patients with small cell lung cancer re-irradiated for brain metastases after prior prophylactic cranial irradiation.
    Lung Cancer. 2016;101:76-81.
    PubMed     Text format     Abstract available


  137. HENDRIKS LE, Brouns AJ, Amini M, Uyterlinde W, et al
    Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
    Lung Cancer. 2016;101:68-75.
    PubMed     Text format     Abstract available


  138. KIM JY, Sun V, Raz DJ, Williams AC, et al
    The impact of lung cancer surgery on quality of life trajectories in patients and family caregivers.
    Lung Cancer. 2016;101:35-39.
    PubMed     Text format     Abstract available


  139. VERONESI G, Novellis P, Voulaz E, Alloisio M, et al
    Robot-assisted surgery for lung cancer: State of the art and perspectives.
    Lung Cancer. 2016;101:28-34.
    PubMed     Text format     Abstract available


  140. THONGPRASERT S, Yang PC, Lee JS, Soo R, et al
    The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients.
    Lung Cancer. 2016;101:137-144.
    PubMed     Text format     Abstract available


  141. NUMAN RC, Berge MT, Burgers JA, Klomp HM, et al
    Peri- and postoperative management of stage I-III Non Small Cell Lung Cancer: Which quality of care indicators are evidence-based?
    Lung Cancer. 2016;101:129-136.
    PubMed     Text format     Abstract available


  142. LAM SK, Leung LL, Li YY, Zheng CY, et al
    Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
    Lung Cancer. 2016;101:111-119.
    PubMed     Text format     Abstract available


  143. TANIZAKI J, Banno E, Togashi Y, Hayashi H, et al
    Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
    Lung Cancer. 2016;101:11-15.
    PubMed     Text format     Abstract available


  144. NOSAKI K, Satouchi M, Kurata T, Yoshida T, et al
    Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study.
    Lung Cancer. 2016;101:1-8.
    PubMed     Text format     Abstract available


    October 2016
  145. REMON J, Girard N, Mazieres J, Dansin E, et al
    Erratum to "Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network" [Lung Cancer, 97 (July 2016), 99-104].
    Lung Cancer. 2016 Oct 6. pii: S0169-5002(16)30483.
    PubMed     Text format    


  146. VANNUCCI F, Gonzalez-Rivas D
    Is VATS lobectomy standard of care for operable non-small cell lung cancer?
    Lung Cancer. 2016;100:114-9.
    PubMed     Text format     Abstract available


  147. BAUML JM, Troxel A, Epperson CN, Cohen RB, et al
    Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety".
    Lung Cancer. 2016;100:110-3.
    PubMed     Text format     Abstract available


  148. SULLIVAN DR, Forsberg CW, Ganzini L, Au DH, et al
    Depression symptom trends and health domains among lung cancer patients in the CanCORS study.
    Lung Cancer. 2016;100:102-9.
    PubMed     Text format     Abstract available


  149. JEPPESEN SS, Hansen NC, Schytte T, Nielsen M, et al
    Comparison of survival of chronic obstructive pulmonary disease patients with or without a localized non-small cell lung cancer.
    Lung Cancer. 2016;100:90-5.
    PubMed     Text format     Abstract available


  150. MITIN T, Jain A, Degnin C, Chen Y, et al
    Current patterns of care for patients with extensive stage small cell lung cancer: Survey of US radiation oncologists on their recommendations regarding thoracic consolidation radiotherapy.
    Lung Cancer. 2016;100:85-9.
    PubMed     Text format     Abstract available


  151. SORENSEN SF, Demuth C, Weber B, Sorensen BS, et al
    Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.
    Lung Cancer. 2016;100:77-84.
    PubMed     Text format     Abstract available


  152. KLUPCZYNSKA A, Derezinski P, Dyszkiewicz W, Pawlak K, et al
    Evaluation of serum amino acid profiles' utility in non-small cell lung cancer detection in Polish population.
    Lung Cancer. 2016;100:71-6.
    PubMed     Text format     Abstract available


  153. JIANG T, Zhai C, Su C, Ren S, et al
    The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis.
    Lung Cancer. 2016;100:63-70.
    PubMed     Text format     Abstract available


  154. GIBELIN C, Couraud S
    Somatic alterations in lung cancer: Do environmental factors matter?
    Lung Cancer. 2016;100:45-52.
    PubMed     Text format     Abstract available


  155. NEUMAIR P, Joos L, Warschkow R, Dutly A, et al
    Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study.
    Lung Cancer. 2016;100:38-44.
    PubMed     Text format     Abstract available


  156. SCAGLIOTTI G, Nishio M, Satouchi M, Valmadre G, et al
    A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy.
    Lung Cancer. 2016;100:20-3.
    PubMed     Text format     Abstract available


    September 2016
  157. ERB CT, Su KW, Soulos PR, Tanoue LT, et al
    Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population.
    Lung Cancer. 2016;99:200-7.
    PubMed     Text format     Abstract available


  158. YOH K, Hosomi Y, Kasahara K, Yamada K, et al
    A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
    Lung Cancer. 2016;99:186-93.
    PubMed     Text format     Abstract available


  159. DAWE DE, Christiansen D, Swaminath A, Ellis PM, et al
    Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2016;99:180-5.
    PubMed     Text format     Abstract available


  160. DAI L, Tsay JC, Li J, Yie TA, et al
    Autoantibodies against tumor-associated antigens in the early detection of lung cancer.
    Lung Cancer. 2016;99:172-9.
    PubMed     Text format     Abstract available


  161. LIN JJ, Ezer N, Sigel K, Mhango G, et al
    The effect of statins on survival in patients with stage IV lung cancer.
    Lung Cancer. 2016;99:137-42.
    PubMed     Text format     Abstract available


  162. USUI K, Sugawara S, Nishitsuji M, Fujita Y, et al
    A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
    Lung Cancer. 2016;99:131-6.
    PubMed     Text format     Abstract available


  163. GAINETDINOV IV, Kapitskaya KY, Rykova EY, Ponomaryova AA, et al
    Hypomethylation of human-specific family of LINE-1 retrotransposons in circulating DNA of lung cancer patients.
    Lung Cancer. 2016;99:127-30.
    PubMed     Text format     Abstract available


  164. TABCHI S, Weng X, Blais N
    Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab.
    Lung Cancer. 2016;99:123-6.
    PubMed     Text format     Abstract available


  165. SAKATA Y, Kawamura K, Shingu N, Ichikado K, et al
    Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.
    Lung Cancer. 2016;99:120-2.
    PubMed     Text format     Abstract available


  166. SMIT EF, Wu YL, Gervais R, Zhou C, et al
    A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
    Lung Cancer. 2016;99:94-101.
    PubMed     Text format     Abstract available


  167. SALANDER P, Lilliehorn S
    To carry on as before: A meta-synthesis of qualitative studies in lung cancer.
    Lung Cancer. 2016;99:88-93.
    PubMed     Text format     Abstract available


  168. SHIEN K, Papadimitrakopoulou VA, Wistuba II
    Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Lung Cancer. 2016;99:79-87.
    PubMed     Text format     Abstract available


  169. SHALLWANI SM, Simmonds MJ, Kasymjanova G, Spahija J, et al
    Quality of life, symptom status and physical performance in patients with advanced non-small cell lung cancer undergoing chemotherapy: an exploratory analysis of secondary data.
    Lung Cancer. 2016;99:69-75.
    PubMed     Text format     Abstract available


  170. KIM HR, Lee GO, Choi KH, Kim DK, et al
    SRSF5: a novel marker for small-cell lung cancer and pleural metastatic cancer.
    Lung Cancer. 2016;99:57-65.
    PubMed     Text format     Abstract available


  171. WIDLAK P, Pietrowska M, Polanska J, Marczyk M, et al
    Serum mass profile signature as a biomarker of early lung cancer.
    Lung Cancer. 2016;99:46-52.
    PubMed     Text format     Abstract available


  172. SAKATA S, Saeki S, Okamoto I, Otsubo K, et al
    Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
    Lung Cancer. 2016;99:41-5.
    PubMed     Text format     Abstract available


  173. JOHNSON AC, Do P, Richard N, Dubos C, et al
    Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.
    Lung Cancer. 2016;99:38-40.
    PubMed     Text format     Abstract available


  174. CAPPUZZO F, Morabito A, Normanno N, Bidoli P, et al
    Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2016;99:31-7.
    PubMed     Text format     Abstract available


  175. PIETANZA MC, Litvak AM, Varghese AM, Krug LM, et al
    A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer.
    Lung Cancer. 2016;99:23-30.
    PubMed     Text format     Abstract available


  176. ZENKE Y, Umemura S, Sugiyama E, Kirita K, et al
    Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer.
    Lung Cancer. 2016;99:1-3.
    PubMed     Text format     Abstract available


    August 2016
  177. LACCETTI AL, Pruitt SL, Xuan L, Halm EA, et al
    Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis.
    Lung Cancer. 2016;98:106-13.
    PubMed     Text format     Abstract available


  178. CHEN YM, Lai CH, Rau KM, Huang CH, et al
    Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.
    Lung Cancer. 2016;98:99-105.
    PubMed     Text format     Abstract available


  179. PINEIRO B, Simmons VN, Palmer AM, Correa JB, et al
    Smoking cessation interventions within the context of Low-Dose Computed Tomography lung cancer screening: A systematic review.
    Lung Cancer. 2016;98:91-8.
    PubMed     Text format     Abstract available


  180. MONNET I, Audigier-Valette C, Girard N, Vergnenegre A, et al
    Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.
    Lung Cancer. 2016;98:84-90.
    PubMed     Text format     Abstract available


  181. BOYER MJ, Gu L, Wang X, Kelsey CR, et al
    Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.
    Lung Cancer. 2016;98:76-8.
    PubMed     Text format     Abstract available


  182. SHIMOJI M, Shimizu S, Sato K, Suda K, et al
    Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Lung Cancer. 2016;98:69-75.
    PubMed     Text format     Abstract available


  183. LI SY, Li Q, Guan WJ, Huang J, et al
    Effects of para-toluenesulfonamide intratumoral injection on non-small cell lung carcinoma with severe central airway obstruction: A multi-center, non-randomized, single-arm, open-label trial.
    Lung Cancer. 2016;98:43-50.
    PubMed     Text format     Abstract available


  184. ZANETTI KA, Wang Z, Aldrich M, Amos CI, et al
    Genome-wide association study confirms lung cancer susceptibility loci on chromosomes 5p15 and 15q25 in an African-American population.
    Lung Cancer. 2016;98:33-42.
    PubMed     Text format     Abstract available


  185. SHOJI F, Morodomi Y, Akamine T, Takamori S, et al
    Predictive impact for postoperative recurrence using the preoperative prognostic nutritional index in pathological stage I non-small cell lung cancer.
    Lung Cancer. 2016;98:15-21.
    PubMed     Text format     Abstract available


  186. CADRANEL J, Park K, Arrieta O, Pless M, et al
    Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
    Lung Cancer. 2016;98:9-14.
    PubMed     Text format     Abstract available


  187. MOK T, Ladrera G, Srimuninnimit V, Sriuranpong V, et al
    Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.
    Lung Cancer. 2016;98:1-8.
    PubMed     Text format     Abstract available


    July 2016
  188. HIDDINGA BI, Pauwels P, Janssens A, van Meerbeeck JP, et al
    O6-Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?
    Lung Cancer. 2016 Jul 18. pii: S0169-5002(16)30412.
    PubMed     Text format     Abstract available


  189. PHILIPPOV PP
    Express of concern on 'Antirecoverin autoantibodies in the patient with non-small cell lung cancer but without cancer-associated retinopathy'.
    Lung Cancer. 2016 Jul 13. pii: S0169-5002(16)30399.
    PubMed     Text format    


  190. HU H, Xu Z, Li C, Xu C, et al
    MiR-145 and miR-203 represses TGF-beta-induced epithelial-mesenchymal transition and invasion by inhibiting SMAD3 in non-small cell lung cancer cells.
    Lung Cancer. 2016;97:87-94.
    PubMed     Text format     Abstract available


  191. GARCIA-VELLOSO MJ, Bastarrika G, de-Torres JP, Lozano MD, et al
    Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.
    Lung Cancer. 2016;97:81-6.
    PubMed     Text format     Abstract available


  192. COSTA G, Thuler LC, Ferreira CG
    Epidemiological changes in the histological subtypes of 35,018 non-small-cell lung cancer cases in Brazil.
    Lung Cancer. 2016;97:66-72.
    PubMed     Text format     Abstract available


  193. YOSHIDA T, Oya Y, Tanaka K, Shimizu J, et al
    Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.
    Lung Cancer. 2016;97:43-7.
    PubMed     Text format     Abstract available


  194. SANCHEZ-SALCEDO P, de-Torres JP, Martinez-Urbistondo D, Gonzalez-Gutierrez J, et al
    The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development.
    Lung Cancer. 2016;97:28-34.
    PubMed     Text format     Abstract available


  195. BRULE SY, Al-Baimani K, Jonker H, Zhang T, et al
    Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.
    Lung Cancer. 2016;97:15-21.
    PubMed     Text format     Abstract available


  196. KENNEDY MP, Hall PS, Callister ME
    Factors affecting hospital costs in lung cancer patients in the United Kingdom.
    Lung Cancer. 2016;97:8-14.
    PubMed     Text format     Abstract available


  197. NAKAGAWA K, Asamura H, Tsuta K, Nagai K, et al
    The novel one-step nucleic acid amplification (OSNA) assay for the diagnosis of lymph node metastasis in patients with non-small cell lung cancer (NSCLC): Results of a multicenter prospective study.
    Lung Cancer. 2016;97:1-7.
    PubMed     Text format     Abstract available


    June 2016
  198. ROBLES AI, Harris CC
    Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer.
    Lung Cancer. 2016 Jun 14. pii: S0169-5002(16)30361.
    PubMed     Text format     Abstract available


  199. ROTHSCHILD SI, Gautschi O, Batliner J, Gugger M, et al
    MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
    Lung Cancer. 2016 Jun 14. pii: S0169-5002(16)30362.
    PubMed     Text format     Abstract available


  200. FINAN KM, Hodge G, Reynolds AM, Hodge S, et al
    Corrigendum to "In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2" [Lung Cancer 53 (3) (September 2006) 273-284].
    Lung Cancer. 2016 Jun 13. pii: S0169-5002(16)30360.
    PubMed     Text format    


  201. LI J, Yu J, Liu A, Wang Y, et al
    Retraction notice to "ss-elemene against human lung cancer via up-regulation of P53 protein expression to promote the release of exosome": LUNG 86/2 (2014) 144-150.
    Lung Cancer. 2016;96:120.
    PubMed     Text format    


  202. WEISS E, Ford JC, Olsen KM, Karki K, et al
    Apparent diffusion coefficient (ADC) change on repeated diffusion-weighted magnetic resonance imaging during radiochemotherapy for non-small cell lung cancer: A pilot study.
    Lung Cancer. 2016;96:113-9.
    PubMed     Text format     Abstract available


  203. HAN JY, Kim HY, Lim KY, Hwangbo B, et al
    A phase II study of nintedanib in patients with relapsed small cell lung cancer.
    Lung Cancer. 2016;96:108-12.
    PubMed     Text format     Abstract available


  204. HSU F, De Caluwe A, Anderson D, Nichol A, et al
    EGFR mutation status on brain metastases from non-small cell lung cancer.
    Lung Cancer. 2016;96:101-7.
    PubMed     Text format     Abstract available


  205. ZHOU L, He J, Xiong W, Liu Y, et al
    Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
    Lung Cancer. 2016;96:93-100.
    PubMed     Text format     Abstract available


  206. XU J, Jin B, Chu T, Dong X, et al
    EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
    Lung Cancer. 2016;96:87-92.
    PubMed     Text format     Abstract available


  207. CREQUIT P, Ruppert AM, Rozensztajn N, Gounant V, et al
    EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
    Lung Cancer. 2016;96:74-7.
    PubMed     Text format     Abstract available


  208. ENOMOTO Y, Inui N, Kato T, Baba T, et al
    Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
    Lung Cancer. 2016;96:63-7.
    PubMed     Text format     Abstract available


  209. KIM HK, Cho JH, Choi YS, Zo JI, et al
    Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.
    Lung Cancer. 2016;96:56-62.
    PubMed     Text format     Abstract available


  210. LI R, Hermann G, Baldini E, Chen A, et al
    Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer.
    Lung Cancer. 2016;96:41-7.
    PubMed     Text format     Abstract available


  211. KHAKWANI A, Hubbard RB, Beckett P, Borthwick D, et al
    Which patients are assessed by lung cancer nurse specialists? A national lung cancer audit study of over 128,000 patients across england.
    Lung Cancer. 2016;96:33-40.
    PubMed     Text format     Abstract available


  212. PATIL T, Aisner DL, Noonan SA, Bunn PA, et al
    Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status.
    Lung Cancer. 2016;96:27-32.
    PubMed     Text format     Abstract available


  213. SAKURAI S, Shirai T, Akamatsu T, Hayashi I, et al
    Endobronchial lesions as a predictor of impaired cough-related quality of life in lung cancer.
    Lung Cancer. 2016;96:25-6.
    PubMed     Text format    


  214. OLIVEIRA MB, Mello FC, Paschoal ME
    The relationship between lung cancer histology and the clinicopathological characteristics of bone metastases.
    Lung Cancer. 2016;96:19-24.
    PubMed     Text format     Abstract available


  215. BENAVENT F, Capobianco CS, Garona J, Cirigliano SM, et al
    CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.
    Lung Cancer. 2016 Jun 1. pii: S0169-5002(16)30352.
    PubMed     Text format     Abstract available


    May 2016
  216. VAVALA T, Monica V, Lo Iacono M, Mele T, et al
    Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research.
    Lung Cancer. 2016 May 31. pii: S0169-5002(16)30348.
    PubMed     Text format     Abstract available


  217. TARTARONE A, Rossi E, Lerose R, Mambella G, et al
    Possible applications of circulating tumor cells in patients with non small cell lung cancer.
    Lung Cancer. 2016 May 31. pii: S0169-5002(16)30349.
    PubMed     Text format     Abstract available


  218. KOMIYA K, Sueoka-Aragane N, Sato A, Hisatomi T, et al
    Erratum to "Expression of Mina53, a novel c-Myc target gene, is a favorable prognostic marker in early stage lung cancer" [Lung Cancer 69/2 (2010) 232-238].
    Lung Cancer. 2016 May 27. pii: S0169-5002(16)30318.
    PubMed     Text format    


  219. AKCA H, Demiray A, Tokgun O, Yokota J, et al
    Erratum to "Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells" [Lung Cancer 73 (3) (2011) 302-309].
    Lung Cancer. 2016 May 24. pii: S0169-5002(16)30319.
    PubMed     Text format    


  220. DAUTZENBERG B, Garelik D
    Patients with lung cancer: Are electronic cigarettes harmful or useful?
    Lung Cancer. 2016 May 20. pii: S0169-5002(16)30323.
    PubMed     Text format     Abstract available


  221. SIWICKY MD, Petrik JJ, Moorehead RA
    Erratum to "The function of IGF-IR in NNK-mediated lung tumorigenesis" [Lung Cancer 71 (1) (2011) 11-18].
    Lung Cancer. 2016 May 5. pii: S0169-5002(16)30306.
    PubMed     Text format    


  222. SORBER L, Zwaenepoel K, Deschoolmeester V, Van Schil PE, et al
    Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Lung Cancer. 2016 May 4. pii: S0169-5002(16)30312.
    PubMed     Text format     Abstract available


  223. O'DOWD EL, Luchtenborg M, Baldwin DR, McKeever TM, et al
    Predicting death from surgery for lung cancer: A comparison of two scoring systems in two European countries.
    Lung Cancer. 2016;95:88-93.
    PubMed     Text format     Abstract available


  224. VAVALA T, Follador A, Tiseo M, Galetta D, et al
    BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.
    Lung Cancer. 2016;95:73-81.
    PubMed     Text format     Abstract available


  225. KANG HN, Kim SH, Yun MR, Kim HR, et al
    ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.
    Lung Cancer. 2016;95:57-64.
    PubMed     Text format     Abstract available


  226. KUDJAWU YC, Chatellier G, Decool E, de Maria F, et al
    Timing in initiating lung cancer treatment after bronchoscopy in France: Study from medico-administrative database.
    Lung Cancer. 2016;95:44-50.
    PubMed     Text format     Abstract available


  227. DOESCH J, Debus D, Meyer C, Papadopoulos T, et al
    Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.
    Lung Cancer. 2016;95:35-8.
    PubMed     Text format     Abstract available


  228. SCHROEDER MC, Tien YY, Wright K, Halfdanarson TR, et al
    Geographic variation in the use of adjuvant therapy among elderly patients with resected non-small cell lung cancer.
    Lung Cancer. 2016;95:28-34.
    PubMed     Text format     Abstract available


  229. BRENNER DR, Yannitsos DH, Farris MS, Johansson M, et al
    Leisure-time physical activity and lung cancer risk: A systematic review and meta-analysis.
    Lung Cancer. 2016;95:17-27.
    PubMed     Text format     Abstract available


  230. MOTH E, McLachlan SA, Veillard AS, Muljadi N, et al
    Patients' preferred and perceived roles in making decisions about adjuvant chemotherapy for non-small-cell lung cancer.
    Lung Cancer. 2016;95:8-14.
    PubMed     Text format     Abstract available


  231. BUTNOR KJ, Brownlee NA, Mahar A, Pavlisko EN, et al
    Diffuse malignant mesothelioma and synchronous lung cancer: A clinicopathological study of 18 cases.
    Lung Cancer. 2016;95:1-7.
    PubMed     Text format     Abstract available


  232. JU L, Han M, Zhao C, Li X, et al
    EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient.
    Lung Cancer. 2016;95:94-7.
    PubMed     Text format     Abstract available


  233. METRO G, Ricciuti B, Chiari R, Baretti M, et al
    Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.
    Lung Cancer. 2016;95:82-7.
    PubMed     Text format     Abstract available


  234. SIEGELE BJ, Shilo K, Chao BH, Carbone DP, et al
    Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literature.
    Lung Cancer. 2016;95:65-72.
    PubMed     Text format     Abstract available


  235. SAKAKURA N, Inaba Y, Yatabe Y, Mizuno T, et al
    Estimation of the pathological invasive size of pulmonary adenocarcinoma using high-resolution computed tomography of the chest: A consideration based on lung and mediastinal window settings.
    Lung Cancer. 2016;95:51-6.
    PubMed     Text format     Abstract available


  236. WANG Q, Zhao L, Yang X, Wei S, et al
    Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
    Lung Cancer. 2016;95:39-43.
    PubMed     Text format     Abstract available


  237. SASSIER M, Mennecier B, Gschwend A, Rein M, et al
    Successful treatment with ceritinib after crizotinib induced hepatitis.
    Lung Cancer. 2016;95:15-6.
    PubMed     Text format     Abstract available


    April 2016
  238. LUNG J, Lin YC, Hung MS, Jiang YY, et al
    A sensitive and high throughput TaqMan-based reverse transcription quantitative polymerase chain reaction assay efficiently discriminates ALK rearrangement from overexpression for lung cancer FFPE specimens.
    Lung Cancer. 2016;94:114-20.
    PubMed     Text format     Abstract available


  239. DICKHOFF C, Dahele M, Paul MA, van de Ven PM, et al
    Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer.
    Lung Cancer. 2016;94:108-13.
    PubMed     Text format     Abstract available


  240. ROSELL A, Rodriguez N, Monso E, Taron M, et al
    Aberrant gene methylation and bronchial dysplasia in high risk lung cancer patients.
    Lung Cancer. 2016;94:102-7.
    PubMed     Text format     Abstract available


  241. VAN DER AALST CM, de Koning HJ
    Biochemical verification of the self-reported smoking status of screened male smokers of the Dutch-Belgian randomized controlled lung cancer screening trial.
    Lung Cancer. 2016;94:96-101.
    PubMed     Text format     Abstract available


  242. CAMERON SJ, Lewis KE, Beckmann M, Allison GG, et al
    The metabolomic detection of lung cancer biomarkers in sputum.
    Lung Cancer. 2016;94:88-95.
    PubMed     Text format     Abstract available


  243. DUDANI S, Leighl NB, Ho C, Pantarotto JR, et al
    Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists.
    Lung Cancer. 2016;94:74-80.
    PubMed     Text format     Abstract available


  244. IMAMURA F, Uchida J, Kukita Y, Kumagai T, et al
    Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.
    Lung Cancer. 2016;94:68-73.
    PubMed     Text format     Abstract available


  245. LOUIE AV, Damhuis RA, Haasbeek CJ, Warner A, et al
    Treatment and survival of second primary early-stage lung cancer, following treatment of head and neck cancer in the Netherlands.
    Lung Cancer. 2016;94:54-60.
    PubMed     Text format     Abstract available


  246. CHEN LY, Molina-Vila MA, Ruan SY, Su KY, et al
    Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2016;94:46-53.
    PubMed     Text format     Abstract available


  247. MENAMIN UC, Cardwell CR, Hughes CM, Murray LM, et al
    Metformin use and survival from lung cancer: A population-based cohort study.
    Lung Cancer. 2016;94:35-9.
    PubMed     Text format     Abstract available


  248. YIN Z, Cui Z, Ren Y, Xia L, et al
    Association between polymorphisms in pre-miRNA genes and risk of lung cancer in a Chinese non-smoking female population.
    Lung Cancer. 2016;94:15-21.
    PubMed     Text format     Abstract available


  249. SZYSZKO TA, Yip C, Szlosarek P, Goh V, et al
    The role of new PET tracers for lung cancer.
    Lung Cancer. 2016;94:7-14.
    PubMed     Text format     Abstract available


    March 2016
  250. PEROL M, Ciuleanu TE, Arrieta O, Prabhash K, et al
    Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
    Lung Cancer. 2016;93:95-103.
    PubMed     Text format     Abstract available


  251. TAVARES E CASTRO A, Clemente J, Carvalho L, Freitas S, et al
    Small-cell lung cancer in never-smokers: A case series.
    Lung Cancer. 2016;93:82-7.
    PubMed     Text format     Abstract available


  252. HIROSE T, Fujita K, Kusumoto S, Oki Y, et al
    Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
    Lung Cancer. 2016;93:69-76.
    PubMed     Text format     Abstract available


  253. TAN CS, Cho BC, Soo RA
    Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Lung Cancer. 2016;93:59-68.
    PubMed     Text format     Abstract available


  254. CHEN YM, Lai CH, Chang HC, Chao TY, et al
    The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors.
    Lung Cancer. 2016;93:47-54.
    PubMed     Text format     Abstract available


  255. HORIIKE A, Takeuchi K, Uenami T, Kawano Y, et al
    Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
    Lung Cancer. 2016;93:43-6.
    PubMed     Text format     Abstract available


  256. TONNIES S, Tonnies M, Kollmeier J, Bauer TT, et al
    Impact of preoperative 18F-FDG PET/CT on survival of resected mono-metastatic non-small cell lung cancer.
    Lung Cancer. 2016;93:28-34.
    PubMed     Text format     Abstract available


  257. VAN DEN BOOGAART VE, de Lussanet QG, Houben RM, de Ruysscher D, et al
    Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib.
    Lung Cancer. 2016;93:20-7.
    PubMed     Text format     Abstract available


  258. MENIAWY TM, Lake RA, McDonnell AM, Millward MJ, et al
    PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
    Lung Cancer. 2016;93:9-16.
    PubMed     Text format     Abstract available


  259. LIM SM, Cho BC, Kim SW, Kang SY, et al
    A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
    Lung Cancer. 2016;93:1-8.
    PubMed     Text format     Abstract available


  260. MENGOLI MC, Barbieri F, Bertolini F, Tiseo M, et al
    K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
    Lung Cancer. 2016;93:55-8.
    PubMed     Text format     Abstract available


  261. LI D, Zhang L, Zhou J, Chen H, et al
    Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT.
    Lung Cancer. 2016;93:35-42.
    PubMed     Text format     Abstract available


  262. VAN GEEL RM, Hendrikx JJ, Vahl JE, van Leerdam ME, et al
    Crizotinib-induced fatal fulminant liver failure.
    Lung Cancer. 2016;93:17-9.
    PubMed     Text format     Abstract available


    February 2016
  263. KATO T, Wada H, Patel P, Hu HP, et al
    Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients.
    Lung Cancer. 2016;92:53-61.
    PubMed     Text format     Abstract available


  264. TSURUGAI Y, Kozuka T, Ishizuka N, Oguchi M, et al
    Relationship between the consolidation to maximum tumor diameter ratio and outcomes following stereotactic body radiotherapy for stage I non-small-cell lung cancer.
    Lung Cancer. 2016;92:47-52.
    PubMed     Text format     Abstract available


  265. KRISHNASWAMY S, Mohammed AK, Amer OE, Tripathi G, et al
    Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
    Lung Cancer. 2016;92:41-6.
    PubMed     Text format     Abstract available


  266. SMIT E, Moro-Sibilot D, Carpeno Jde C, Lesniewski-Kmak K, et al
    Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study.
    Lung Cancer. 2016;92:35-40.
    PubMed     Text format     Abstract available


  267. HAMES ML, Chen H, Iams W, Aston J, et al
    Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2016;92:29-34.
    PubMed     Text format     Abstract available


  268. GUERRERO E, Ahmed M
    The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer.
    Lung Cancer. 2016;92:22-8.
    PubMed     Text format     Abstract available


  269. MALOTTKI K, Popat S, Deeks JJ, Riley RD, et al
    Problems of variable biomarker evaluation in stratified medicine research-A case study of ERCC1 in non-small-cell lung cancer.
    Lung Cancer. 2016;92:1-7.
    PubMed     Text format     Abstract available


  270. KODITYAL S, Elvin JA, Squillace R, Agarwal N, et al
    A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
    Lung Cancer. 2016;92:19-21.
    PubMed     Text format     Abstract available


  271. CAUMONT C, Veillon R, Gros A, Laharanne E, et al
    Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
    Lung Cancer. 2016;92:15-8.
    PubMed     Text format     Abstract available


  272. SCHMIDT LH, Kuemmel A, Schliemann C, Schulze A, et al
    Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC.
    Lung Cancer. 2016;92:8-14.
    PubMed     Text format     Abstract available


    January 2016
  273. KINOSHITA T, Fujii H, Hayashi Y, Kamiyama I, et al
    Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
    Lung Cancer. 2016;91:56-66.
    PubMed     Text format     Abstract available


  274. RIEBER J, Deeg A, Ullrich E, Foerster R, et al
    Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC).
    Lung Cancer. 2016;91:41-7.
    PubMed     Text format     Abstract available


  275. SUDA K, Murakami I, Sakai K, Tomizawa K, et al
    Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
    Lung Cancer. 2016;91:36-40.
    PubMed     Text format     Abstract available


  276. FIELD JK, Devaraj A, Duffy SW, Baldwin DR, et al
    CT screening for lung cancer: Is the evidence strong enough?
    Lung Cancer. 2016;91:29-35.
    PubMed     Text format     Abstract available


  277. TISSOT C, Couraud S, Tanguy R, Bringuier PP, et al
    Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Lung Cancer. 2016;91:23-8.
    PubMed     Text format     Abstract available


  278. KIM G, An HJ, Lee MJ, Song JY, et al
    Hsa-miR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancer.
    Lung Cancer. 2016;91:15-22.
    PubMed     Text format     Abstract available


  279. DEBIEUVRE D, Oster JP, Riou R, Berruchon J, et al
    The new face of non-small-cell lung cancer in men: Results of two French prospective epidemiological studies conducted 10 years apart.
    Lung Cancer. 2016;91:1-6.
    PubMed     Text format     Abstract available


  280. CALLISTER ME, Baldwin DR
    How should pulmonary nodules be optimally investigated and managed?
    Lung Cancer. 2016;91:48-55.
    PubMed     Text format     Abstract available


  281. SARUWATARI K, Ikemura S, Sekihara K, Kuwata T, et al
    Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.
    Lung Cancer. 2016;91:7-14.
    PubMed     Text format     Abstract available


  282. BAAS P, van Meerbeeck J
    Money rules the world.
    Lung Cancer. 2016;91:77-8.
    PubMed     Text format    


  283. OU SH, Milliken JC, Azada MC, Miller VA, et al
    ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
    Lung Cancer. 2016;91:70-2.
    PubMed     Text format     Abstract available


    December 2015
  284. DAUTZENBERG B, Garelik D
    Patients with lung cancer: Are electronic cigarettes harmful, useful?
    Lung Cancer. 2015 Dec 24. pii: S0169-5002(15)30123.
    PubMed     Text format     Abstract available


  285. MORO-SIBILOT D, Smit E, de Castro Carpeno J, Lesniewski-Kmak K, et al
    Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.
    Lung Cancer. 2015;90:427-32.
    PubMed     Text format     Abstract available


  286. KUSAGAYA H, Inui N, Karayama M, Fujisawa T, et al
    Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2015;90:410-6.
    PubMed     Text format     Abstract available


  287. SCHMID-BINDERT G, Engel-Riedel W, Reck M, Schuette W, et al
    A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.
    Lung Cancer. 2015;90:397-404.
    PubMed     Text format     Abstract available


  288. RICARDI U, Badellino S, Filippi AR
    Stereotactic body radiotherapy for early stage lung cancer: History and updated role.
    Lung Cancer. 2015;90:388-96.
    PubMed     Text format     Abstract available


  289. LI A, Niu FY, Han JF, Lou NN, et al
    Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2015;90:375-80.
    PubMed     Text format     Abstract available


    November 2015
  290. VERGNE F, Quere G, Andrieu-Key S, Descourt R, et al
    ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
    Lung Cancer. 2015 Nov 10. pii: S0169-5002(15)30106.
    PubMed     Text format     Abstract available


  291. VALLEE A, Audigier-Valette C, Herbreteau G, Merrien J, et al
    Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation.
    Lung Cancer. 2015 Nov 7. pii: S0169-5002(15)30104.
    PubMed     Text format    


    October 2015
  292. HOWELL M, Chiramel J, Flaum N, Lewis A, et al
    Outcomes of octogenarian (>/=80 yo) patients with advanced non-small cell lung cancer (NSCLC): A single institution experience at the Christie Hospital.
    Lung Cancer. 2015 Oct 28. pii: S0169-5002(15)30094.
    PubMed     Text format    


  293. VAN DER LINDEN N, Bongers ML, Coupe VM, Smit EF, et al
    Costs of non-small cell lung cancer in the Netherlands.
    Lung Cancer. 2015 Oct 17. pii: S0169-5002(15)30084.
    PubMed     Text format     Abstract available


  294. YOKOUCHI H, Ishida T, Yamazaki S, Kikuchi H, et al
    Prognostic impact of clinical variables on surgically resected small-cell lung cancer: Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A).
    Lung Cancer. 2015 Oct 14. pii: S0169-5002(15)30079.
    PubMed     Text format     Abstract available


  295. YOSHIDA T, Yoh K, Niho S, Umemura S, et al
    RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
    Lung Cancer. 2015 Oct 9. pii: S0169-5002(15)30069.
    PubMed     Text format     Abstract available


    July 2015
  296. LEE MS, Liu CY, Su L, Christiani DC, et al
    Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung.
    Lung Cancer. 2015;89:8-12.
    PubMed     Text format     Abstract available


  297. DAVEY P, Ennis M, Aviv R
    Prophylactic cranial irradiation (PCI). Still a no-brainer?
    Lung Cancer. 2015;89:4-7.
    PubMed     Text format     Abstract available


  298. CHAUDHURI AA, Tang C, Binkley MS, Jin M, et al
    Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
    Lung Cancer. 2015;89:50-6.
    PubMed     Text format     Abstract available


  299. HSIEH MS, Lee YH, Chen JS, Lee JM, et al
    Mixed mucoepidermoid carcinoma and adenocarcinoma of the lung: Two cases with unusual histologic features.
    Lung Cancer. 2015;89:80-3.
    PubMed     Text format     Abstract available


  300. NAKAMURA S, Fukui T, Kawaguchi K, Fukumoto K, et al
    Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 lung adenocarcinoma?
    Lung Cancer. 2015;89:38-42.
    PubMed     Text format     Abstract available


  301. AL-AMERI A, Malhotra P, Thygesen H, Plant PK, et al
    Risk of malignancy in pulmonary nodules: A validation study of four prediction models.
    Lung Cancer. 2015;89:27-30.
    PubMed     Text format     Abstract available


    May 2015
  302. TSAI TH, Wu SG, Hsieh MS, Yu CJ, et al
    Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Lung Cancer. 2015;88:208-14.
    PubMed     Text format     Abstract available


  303. SORENSEN SF, Carus A, Meldgaard P
    Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC.
    Lung Cancer. 2015;88:167-73.
    PubMed     Text format     Abstract available


  304. MAO K, Liu F, Liu X, Khuri FR, et al
    Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.
    Lung Cancer. 2015;88:131-8.
    PubMed     Text format     Abstract available


  305. WANG P, Lu S, Mao H, Bai Y, et al
    Identification of biomarkers for the detection of early stage lung adenocarcinoma by microarray profiling of long noncoding RNAs.
    Lung Cancer. 2015;88:147-53.
    PubMed     Text format     Abstract available


  306. WU KL, Tsai MJ, Yang CJ, Chang WA, et al
    Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
    Lung Cancer. 2015;88:187-94.
    PubMed     Text format     Abstract available


  307. OU SH, Greenbowe J, Khan ZU, Azada MC, et al
    I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Lung Cancer. 2015;88:231-4.
    PubMed     Text format     Abstract available


  308. FUKUHARA T, Maemondo M, Inoue A, Kobayashi K, et al
    Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.
    Lung Cancer. 2015;88:181-6.
    PubMed     Text format     Abstract available


    April 2015
  309. REIS H, Herold T, Ting S, Worm K, et al
    HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
    Lung Cancer. 2015;88:34-41.
    PubMed     Text format     Abstract available


  310. LE X, Desai NV, Majid A, Karp RS, et al
    De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.
    Lung Cancer. 2015;88:70-3.
    PubMed     Text format     Abstract available


  311. RANGACHARI D, Yamaguchi N, VanderLaan PA, Folch E, et al
    Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.
    Lung Cancer. 2015;88:108-11.
    PubMed     Text format     Abstract available


  312. WIECKOWSKI S, Hemmerle T, Prince SS, Schlienger BD, et al
    Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
    Lung Cancer. 2015;88:9-15.
    PubMed     Text format     Abstract available


  313. SELLA T, Botser D, Navon R, Biran H, et al
    Preferences for disclosure of disease related information among thoracic cancer patients.
    Lung Cancer. 2015;88:100-3.
    PubMed     Text format     Abstract available


  314. DE GREVE J, Moran T, Graas MP, Galdermans D, et al
    Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
    Lung Cancer. 2015;88:63-9.
    PubMed     Text format     Abstract available


  315. KIM MY, Koh J, Kim S, Go H, et al
    Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Lung Cancer. 2015;88:24-33.
    PubMed     Text format     Abstract available


  316. GRIFFIOEN GH, Louie AV, de Bree R, Smit EF, et al
    Second primary lung cancers following a diagnosis of primary head and neck cancer.
    Lung Cancer. 2015;88:94-9.
    PubMed     Text format     Abstract available


    March 2015
  317. WILLIAMS M, Liu ZW, Hunter A, Macbeth F, et al
    An updated systematic review of lung chemo-radiotherapy using a new evidence aggregation method.
    Lung Cancer. 2015;87:290-5.
    PubMed     Text format     Abstract available


  318. PELOSI G, Barbareschi M, Cavazza A, Graziano P, et al
    Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal.
    Lung Cancer. 2015;87:226-31.
    PubMed     Text format     Abstract available


  319. JIANG L, He J, Shi X, Shen J, et al
    Prognosis of synchronous and metachronous multiple primary lung cancers: systematic review and meta-analysis.
    Lung Cancer. 2015;87:303-10.
    PubMed     Text format     Abstract available


  320. ROBESOVA B, Bajerova M, Hausnerova J, Skrickova J, et al
    Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.
    Lung Cancer. 2015;87:318-20.
    PubMed     Text format     Abstract available


  321. TONG KM, Laskin J, Ho C
    Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.
    Lung Cancer. 2015;87:296-302.
    PubMed     Text format     Abstract available


  322. MEDJBER K, Freidja ML, Grelet S, Lorenzato M, et al
    Role of nicotinic acetylcholine receptors in cell proliferation and tumour invasion in broncho-pulmonary carcinomas.
    Lung Cancer. 2015;87:258-64.
    PubMed     Text format     Abstract available


  323. YANG Y, Yang Y, Zhou X, Song X, et al
    EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
    Lung Cancer. 2015;87:272-7.
    PubMed     Text format     Abstract available


    February 2015
  324. KOCHER F, Hilbe W, Seeber A, Pircher A, et al
    Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.
    Lung Cancer. 2015;87:193-200.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: